The FDA approval of the biologic drug Dupixent for allergic fungal rhinosinusitis may help patients living with this challenging condition and help them avoid repeat surgeries. The U.S. Food and Drug ...

The FDA has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis.

Phase 3 LIBERTY-AIMS results showed dupilumab reduced nasal polyp size and sinus symptoms in adults and children with allergic fungal rhinosinusitis.

Priority Review approval extends dupilumab into AFRS with prior surgery, expanding sino-nasal indications beyond CRSwNP and representing the ninth FDA-approved indication across type 2 inflammatory ...

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery ...

The FDA has approved dupilumab (Dupixent) to treat allergic fungal rhinosinusitis in adults and children ages 6 years and older with a history of sinonasal surgery. The approval makes the drug the ...

Often the worst symptoms of nasal polyps happen when they grow large or you have multiple nasal polyps. Infection is more common when this happens. Certain medications work specifically to shrink ...

Nasal polyps are teardrop-shaped, soft tissue growths that form in the lining of your nasal cavity and sinuses (the hollow spaces in the bones of your face). Nasal polyps are benign, which means they ...

The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) with a ...